# Hamps Bio (NSE: HAMPS) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/HAMPS · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹22 Cr, it ranks 3540th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Pharmaceutical Retailers.

Its return on equity was 3.4% in FY25. Promoters held 71.99% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹22 Cr |
| ROE | 3.4% (FY25) |
| ROCE | 5.0% (FY25) |
| Debt to equity | 0.34 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹7 Cr | ₹0 Cr |
| FY24 | ₹6 Cr | ₹1 Cr |
| FY23 | ₹6 Cr | ₹0 Cr |
| FY22 | ₹5 Cr | ₹0 Cr |
| FY21 | ₹4 Cr | −₹0 Cr |
| FY20 | ₹5 Cr | −₹0 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 71.99%
- Non-institutions: 28.01%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [SUPHA PHARMACHE](https://app.pivotnow.in/stock/SUPHA) | — | ₹25 Cr | — | — |
| [Transgene Biote](https://app.pivotnow.in/stock/TRABI) | — | ₹23 Cr | — | — |
| [Rekvina Labs](https://app.pivotnow.in/stock/VINRKLB) | — | ₹22 Cr | — | — |
| [Adeshwar Medite](https://app.pivotnow.in/stock/ADESHWAR) | — | ₹21 Cr | — | — |
| [Maitri](https://app.pivotnow.in/stock/MAITRI) | — | ₹19 Cr | — | — |
| [Desh Rakshak](https://app.pivotnow.in/stock/DESHRAK) | — | ₹19 Cr | — | — |

## Questions and answers

### What is the market cap of Hamps Bio?

Hamps Bio's market capitalisation is ₹22 Cr (₹22 Cr) at the 22 Oct 2026 close, ranking 3540th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Hamps Bio?

Return on equity was 3.4% in FY25 and return on capital employed was 5.0% in FY25 (standalone figures).

### Is Hamps Bio a debt-free company?

No. Hamps Bio's debt-to-equity ratio was 0.34 in FY25, with total debt of ₹2 Cr.

### What is the shareholding pattern of Hamps Bio?

As of 31 Mar 2026: promoters 71.99%, non-institutions 28.01%.

### Who are Hamps Bio's competitors?

The listed Pharma & Healthcare companies closest to Hamps Bio by market cap are SUPHA PHARMACHE, Transgene Biote, Rekvina Labs, Adeshwar Medite, Maitri and Desh Rakshak.

### Is Hamps Bio a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Hamps Bio's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on HAMPS against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.